$PVLA

$126.23 +$1.13 (0.9%) Close

$PVLA Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Company Executives

$PVLA Management Team

Dr. David Osborne

Chief Innovation Officer

Age 64

Compensation -

Sex Male

Mr. George Jenkins

Independent Chairman of the Board

Age 73

Compensation $318.1K USD

Sex Male

Mr. Wesley Kaupinen

President

Chief Executive Officer

Founder

Director

Age 47

Compensation $5.436M USD

Sex Male

Mr. Matthew Korenberg

Chief Financial Officer

Age 50

Compensation -

Sex Male

Ms. Kathleen Goin

Chief Operating Officer

Age 55

Compensation $1.125M USD

Sex Female

Dr. Jeffrey Martini

Chief Scientific Officer

Age 47

Compensation $1.867M USD

Sex Male

Name / Title	Age	Compensation	Sex
Dr. David Osborne Chief Innovation Officer	64	-	Male
Mr. George Jenkins Independent Chairman of the Board	73	$318.1K USD	Male
Mr. Wesley Kaupinen President Chief Executive Officer Founder Director	47	$5.436M USD	Male
Mr. Matthew Korenberg Chief Financial Officer	50	-	Male
Ms. Kathleen Goin Chief Operating Officer	55	$1.125M USD	Female
Dr. Jeffrey Martini Chief Scientific Officer	47	$1.867M USD	Male

Board of Directors

From the proxy statement filed Apr 30, 2026

Directors

serving now

Independent

0 of 1

stated in the proxy; 6 not stated

Average tenure

2.9 years

from year joined

CEO also chairs the board

Not stated

no chair stated

Director	Age	On board	Independent	Committees	Other public boards	2025 pay
George M. Jenkins	74	2024 2 years	Not stated	Audit · Chair Compensation	None stated	$303,255
Todd C. Davis	65	2024 2 years	Not stated	Compensation · Chair Nominating and Corporate Governance	Ligand Pharmaceuticals Incorporated, Pelthos Therapeutics Inc.	$269,755
John Doux	57	2026 0 years	Not stated	None stated	None stated	Not stated
Wesley H. Kaupinen CEO	48	2024 2 years	Not independent	None stated	None stated	Paid as CEO
Christopher Kiritsy	61	2016 10 years	Not stated	Audit Nominating and Corporate Governance	None stated	$267,255
Elaine J. Heron, Ph.D.	78	2024 2 years	Not stated	Audit Nominating and Corporate Governance · Chair	Vaxart, Inc.	$271,255
Tadd S. Wessel	50	2024 2 years	Not stated	Compensation Nominating and Corporate Governance	None stated	$264,755

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

2 disclosed in the proxy filed Apr 30, 2026

BVF

held more than 5% of Pieris’ voting securities

Amount not stated

BVF, with other PIPE Investors, agreed to purchase approximately 3,154,241 shares of Pieris common stock and/or Pre-Funded Warrants in the PIPE Financing under a Purchase Agreement dated July 23, 2024

With Pieris Open in proxy

Directors and executive officers of Pieris

directors and executive officers of Pieris

Amount not stated

Indemnification agreements between Pieris and each of its directors and executive officers

With Pieris Open in proxy

Comments

Company Executives

$PVLA Management Team

Dr. David Osborne

Mr. George Jenkins

Mr. Wesley Kaupinen

Mr. Matthew Korenberg

Ms. Kathleen Goin

Dr. Jeffrey Martini

Board of Directors

Related-party transactions